Interferon betaisalsolicensedatthoughused muchesscommonty)for use in patients withasingle
demyelinatinqeventiftissevereandthepatiemtisthouahttobeathiahrskofdevelopinqMS.Interferon
beta-lbisalsolicensedforuse
thiscondition has
oatients with secondary proqressiveMS but itsefficacy
notlicensedforthetreatmentof primary progressiveMS.
notbeenconfrmed
tisalsoimportanttounderstandthatjust becauseamedicationhasbeenlcensed,does notmeanthattis
availableforprescriptionontheNHS.Thisrequires furtherauthorisationthrouqh processessuch astheNCE
Technoloqy Appraisauscheme.Toadd furthercomplication,NCE actually rejected interferon betaand
qlatiramer acetate(copaxone)foruse in MS.However,their usewasutimatety alowved throuahtheadventof
theNSrsk-sharing scheme
@1MIN NDOCRINE
